Physician’s WeeklyQ&A: Using Coronary Artery Calcium Scoring in ASCVD Risk Prediction

ℹ️ Observational Association Only Evidence

A longitudinal observational analysis evaluated whether coronary artery calcium (CAC) scoring improves ASCVD risk prediction beyond the PREVENT-ASCVD equations. Across adults aged 45 to 79 years, adding CAC produced only modest gains in discrimination and risk classification overall. Interview commentary from study author Nilay Shah, MD, MPH, emphasized that findings support current prevention guidelines favoring selective CAC use rather than routine screening. The greatest clinical utility appears in patients with borderline (3% to <5%) or intermediate (5% to <10%) estimated ASCVD risk, where CAC results may help refine risk discussions and statin decision-making.

Clinical Considerations

• Addition of CAC to PREVENT equations provided only modest incremental improvement in 10-year ASCVD risk prediction across risk categories.
• Reclassification benefits were greatest among patients with borderline and intermediate estimated risk, supporting selective rather than universal CAC use.
• For patients already classified as high risk, CAC rarely changes management because lipid-lowering therapy is generally indicated regardless of calcium burden.
• For low-risk individuals, routine CAC scanning may offer limited incremental value while increasing exposure to radiation and downstream testing.
• In intermediate-risk patients, a CAC score of zero may support downward risk reclassification, whereas detectable calcium may support more aggressive preventive strategies.
• Findings may not fully generalize to younger adults, and uncertainty remains regarding optimal CAC use in adults under age 45 and in populations with potentially underestimated ASCVD risk.

Practice Applications

• Consider CAC scoring primarily when uncertainty remains after traditional risk assessment and shared decision-making.
• Interpret CAC results within the context of PREVENT risk estimates rather than as a standalone measure of cardiovascular risk.
• Recognize that routine CAC testing is unlikely to alter management for most patients already categorized as low or high risk.
• Discuss CAC as a potential risk-refinement tool for borderline-risk patients where treatment thresholds remain uncertain.
• Evaluate additional risk-enhancing factors, including inflammatory markers, reproductive history, and family history, alongside CAC findings.